MA38630A1 - Récepteur de l'antigène chimère spécifique de cd19 et ses utilisations - Google Patents
Récepteur de l'antigène chimère spécifique de cd19 et ses utilisationsInfo
- Publication number
- MA38630A1 MA38630A1 MA38630A MA38630A MA38630A1 MA 38630 A1 MA38630 A1 MA 38630A1 MA 38630 A MA38630 A MA 38630A MA 38630 A MA38630 A MA 38630A MA 38630 A1 MA38630 A1 MA 38630A1
- Authority
- MA
- Morocco
- Prior art keywords
- car
- present
- relates
- chimeric antigen
- antigen receptor
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 208000004736 B-Cell Leukemia Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 108020001756 ligand binding domains Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des récepteurs de l'antigène chimère (car). Les car sont capables de rediriger la spécificité et la réactivité des cellules immunes vers une cible sélectionnée, par exploitation des propriétés des domaines de liaison au ligand. En particulier, la présente invention concerne un récepteur de l'antigène chimère dans lequel la liaison du ligand extracellulaire est un scfv dérivé d'un anticorps monoclonal anti-cd19, de préférence 4g7. La présente invention concerne aussi des polynucléotides, des vecteurs codant pour ledit car, et des cellules isolées exprimant ledit car sur leur surface. La présente invention concerne aussi des procédés de manipulation génétique de cellules immunes exprimant le 4g7-car sur leur surface, qui confère à la cellule transduite un état "activé" prolongé. La présente invention est particulièrement utile pour le traitement des lymphomes et de la leucémie à cellules b.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/892,805 US11603539B2 (en) | 2012-05-25 | 2013-05-13 | Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy |
US201361888259P | 2013-10-08 | 2013-10-08 | |
PCT/EP2014/059662 WO2014184143A1 (fr) | 2013-05-13 | 2014-05-12 | Récepteur de l'antigène chimère spécifique de cd19 et ses utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38630A1 true MA38630A1 (fr) | 2017-07-31 |
MA38630B2 MA38630B2 (fr) | 2021-08-31 |
Family
ID=51897790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38630A MA38630B2 (fr) | 2013-05-13 | 2014-05-12 | Récepteur de l'antigène chimère spécifique de cd19 et ses utilisations |
Country Status (30)
Country | Link |
---|---|
US (1) | US20210000869A9 (fr) |
EP (3) | EP3546572B1 (fr) |
JP (2) | JP6491643B2 (fr) |
KR (1) | KR102248157B1 (fr) |
CN (2) | CN105431532B (fr) |
AU (2) | AU2014267436B2 (fr) |
BR (1) | BR112015028387B1 (fr) |
CA (1) | CA2911292C (fr) |
DK (1) | DK3546572T3 (fr) |
EA (2) | EA201990575A3 (fr) |
ES (1) | ES2930431T3 (fr) |
FI (2) | FI3546572T3 (fr) |
HK (2) | HK1222678A1 (fr) |
HR (1) | HRP20221393T1 (fr) |
HU (1) | HUE060901T2 (fr) |
LT (1) | LT2997141T (fr) |
MA (1) | MA38630B2 (fr) |
MX (1) | MX2015015662A (fr) |
MY (1) | MY172897A (fr) |
PH (1) | PH12015502479B1 (fr) |
PL (1) | PL2997141T3 (fr) |
PT (1) | PT2997141T (fr) |
RS (1) | RS63798B1 (fr) |
RU (1) | RU2727447C2 (fr) |
SA (1) | SA515370135B1 (fr) |
SG (2) | SG10201708896WA (fr) |
SI (1) | SI2997141T1 (fr) |
TW (1) | TWI636992B (fr) |
UA (1) | UA118106C2 (fr) |
WO (1) | WO2014184143A1 (fr) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
PL2855667T3 (pl) | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
US11077144B2 (en) | 2013-05-13 | 2021-08-03 | Cellectis | CD19 specific chimeric antigen receptor and uses thereof |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
LT3066201T (lt) | 2013-11-07 | 2018-08-10 | Editas Medicine, Inc. | Su crispr susiję būdai ir kompozicijos su valdančiomis grnr |
US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
JP2017504601A (ja) * | 2013-12-20 | 2017-02-09 | セレクティスCellectis | 免疫療法のためにマルチインプットシグナル感受性t細胞を操作する方法 |
US10189908B2 (en) | 2014-02-05 | 2019-01-29 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
JP2017533729A (ja) * | 2014-10-24 | 2017-11-16 | ベーセーエルテー ホールディングス ベーフェー | T細胞ベースの免疫療法薬 |
US20170296623A1 (en) * | 2014-12-17 | 2017-10-19 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
WO2016123143A1 (fr) | 2015-01-26 | 2016-08-04 | The University Of Chicago | Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer |
BR112017015453A2 (pt) | 2015-01-26 | 2018-01-23 | Cellectis | células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides |
EP3250609A4 (fr) | 2015-01-26 | 2018-07-11 | The University of Chicago | Agents de liaison à l'il13ra alpha 2 et leur utilisation dans le traitement du cancer |
CN114230670A (zh) * | 2015-02-27 | 2022-03-25 | 美商生物细胞基因治疗有限公司 | 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法 |
GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
CN107980046B (zh) | 2015-04-13 | 2021-12-24 | 辉瑞公司 | 靶向b细胞成熟抗原的嵌合抗原受体 |
GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
EP3466967A1 (fr) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions et méthodes de reprogrammation de tcr au moyen de protéines de fusion |
CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
CN107849112B (zh) | 2015-06-25 | 2022-04-01 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
CA2994746A1 (fr) | 2015-08-11 | 2017-02-16 | Cellectis | Cellules pour l'immunotherapie modifiees afin de cibler l'antigene cd38 et pour inactiver le gene cd38 |
JP7299021B2 (ja) * | 2015-09-11 | 2023-06-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体関連の直交性サイトカイン/受容体ペア |
MX2018003533A (es) | 2015-09-24 | 2019-04-25 | Abvitro Llc | Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso. |
WO2017070633A2 (fr) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Protéines cas9 évoluées pour l'édition génétique |
CA3003144A1 (fr) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions et methodes de transduction tumorale |
WO2017075537A1 (fr) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions et méthodes pour le du traitement du cancer |
GB201519900D0 (en) * | 2015-11-11 | 2015-12-23 | Ucl Business Plc | Chimeric antigen receptor |
BR112018014585A2 (pt) | 2016-01-21 | 2018-12-11 | Pfizer | receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii |
CN107298715B (zh) * | 2016-04-15 | 2021-05-04 | 阿思科力(苏州)生物科技有限公司 | Slit2D2-嵌合抗原受体及其应用 |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CN109503721B (zh) * | 2016-05-31 | 2023-03-07 | 上海恒润达生生物科技股份有限公司 | 靶向cd19的嵌合抗原受体及其用途 |
CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
PL240585B1 (pl) | 2016-07-18 | 2022-05-02 | Helix Biopharma Corp | Chimeryczny receptor antygenowy (CAR), komórki immunologiczne zawierające CAR oraz kompozycja farmaceutyczna je zawierająca do leczenia nowotworów |
US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
EP3497214B1 (fr) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Protéines de fusion cas9-recombinase programmables et utilisations associées |
WO2018039438A1 (fr) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases |
CN109789164B (zh) * | 2016-08-30 | 2023-04-28 | 亘喜生物科技(上海)有限公司 | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 |
KR20190046854A (ko) | 2016-09-14 | 2019-05-07 | 얀센 바이오테크 인코포레이티드 | Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도 |
WO2018058432A1 (fr) * | 2016-09-28 | 2018-04-05 | 李华顺 | Molécule de récepteur d'antigène chimérique recombinant polygénique et son utilisation |
ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
EP3525804A4 (fr) * | 2016-10-11 | 2020-09-09 | Minerva Biotechnologies Corporation | Anticorps anti-muc1* humanisés et utilisation de l'enzyme de clivage |
CA3039928A1 (fr) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Administration d'aav d'editeurs de nucleobases |
CA3044593A1 (fr) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion |
WO2018119359A1 (fr) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
US11767512B2 (en) | 2017-04-13 | 2023-09-26 | Cellectis | Sequence specific reagents targeting CCR5 in primary hematopoietic cells |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
AU2018278321A1 (en) | 2017-06-02 | 2019-11-21 | Pfizer Inc. | Chimeric antigen receptors targeting FLT3 |
EP3645036A1 (fr) | 2017-06-30 | 2020-05-06 | Cellectis | Immunothérapie cellulaire pour une administration répétitive |
US11161897B2 (en) | 2017-07-17 | 2021-11-02 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type III domains and methods of using the same |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2019079347A1 (fr) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Utilisations d'éditeurs de bases adénosine |
PE20211266A1 (es) * | 2017-10-31 | 2021-07-19 | Allogene Therapeutics Inc | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas |
EP3703689A1 (fr) | 2017-11-01 | 2020-09-09 | Allogene Therapeutics, Inc. | Polypeptides de caspase-9 modifiés et leurs procédés d'utilisation |
WO2019106163A1 (fr) | 2017-12-01 | 2019-06-06 | Cellectis | Reprogrammation de cellules immunitaires primaires génétiquement modifiées |
AU2018379502A1 (en) * | 2017-12-06 | 2020-06-18 | Abclon Inc. | Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same, and use thereof |
EP3728330A4 (fr) * | 2017-12-23 | 2021-12-08 | Uwell Biopharma Inc. | Composition pharmaceutique de récepteur chimérique et procédé associé |
AU2019216420A1 (en) | 2018-02-01 | 2020-08-20 | Pfizer Inc. | Chimeric antigen receptors targeting CD70 |
WO2019152705A1 (fr) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Anticorps spécifiques à cd70 et leurs utilisations |
PE20201342A1 (es) | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
EP3820901A1 (fr) * | 2018-07-09 | 2021-05-19 | Oslo Universitetssykehus HF | Deux récepteurs antigéniques chimériques se liant de manière spécifique à cd19 et igkappa |
EP3887507A1 (fr) | 2018-11-30 | 2021-10-06 | Janssen Biotech, Inc. | Lymphocytes t gamma delta et leurs utilisations |
RU2742000C2 (ru) * | 2019-03-13 | 2021-02-01 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор |
AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
KR20220002888A (ko) | 2019-04-19 | 2022-01-07 | 알로젠 테라퓨틱스 인코포레이티드 | 4g7-유래 키메라 항원 수용체에 대한 항체 |
KR20220004076A (ko) | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 리툭시맙-내성 키메라 항원 수용체 및 이의 용도 |
BR112022003471A2 (pt) | 2019-08-27 | 2022-05-24 | Janssen Biotech Inc | Sistema receptor de antígeno quimérico e usos do mesmo |
CN112079934B (zh) * | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
MX2022010824A (es) | 2020-03-03 | 2022-11-30 | Janssen Biotech Inc | Células t ¿¿ y usos de estas. |
MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
KR20230019843A (ko) | 2020-05-08 | 2023-02-09 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물 |
US20220023346A1 (en) | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
US20220031751A1 (en) | 2020-08-03 | 2022-02-03 | Kyverna Therapeutics, Inc. | Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same |
US20230321239A1 (en) | 2020-08-14 | 2023-10-12 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptor t cells for treating autoimmunity |
CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
WO2022165419A1 (fr) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Méthodes pour augmenter la fonction des lymphocytes t |
WO2022234158A1 (fr) * | 2021-05-06 | 2022-11-10 | Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) | Thérapie par lymphocytes t avec un récepteur antigénique chimérique spécifique de cd19 |
WO2022266075A1 (fr) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Méthodes et matériels pour le traitement du cancer à l'aide de constructions de car ayant un domaine intracellulaire comprenant un domaine stap et un domaine kinase ou un domaine stap et un domaine phosphatase |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2002077029A2 (fr) * | 2000-11-07 | 2002-10-03 | City Of Hope | Cellules immunitaires specifiques a cd19 redirigees |
EP2059536B1 (fr) * | 2006-08-14 | 2014-01-08 | Xencor, Inc. | Anticorps optimisés ciblant cd19 |
US20080131415A1 (en) * | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
PT2211904T (pt) * | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
WO2009091826A2 (fr) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions et procédés associés à un récepteur d'antigène chimérique spécifique du cd19 humain (h-car) |
EP4032552B1 (fr) * | 2008-08-26 | 2023-10-04 | City of Hope | Procédé et compositions pour fonctionnement amélioré d'effecteur antitumoral de lymphocytes t |
WO2012050374A2 (fr) * | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunothérapie contre les tumeurs solides |
JP5947311B2 (ja) * | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変t細胞の使用 |
US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
US20120245996A1 (en) | 2011-03-22 | 2012-09-27 | Jonathan Mendez | System and method for intent-based content matching |
MX359513B (es) * | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
ES2728436T3 (es) | 2011-04-05 | 2019-10-24 | Cellectis | Método para la generación de TALE-nucleasas compactas y usos de la mismas |
US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
AU2012290342A1 (en) * | 2011-07-29 | 2014-01-30 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
US10421960B2 (en) * | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
-
2014
- 2014-05-12 AU AU2014267436A patent/AU2014267436B2/en active Active
- 2014-05-12 MA MA38630A patent/MA38630B2/fr unknown
- 2014-05-12 WO PCT/EP2014/059662 patent/WO2014184143A1/fr active Application Filing
- 2014-05-12 PT PT147234363T patent/PT2997141T/pt unknown
- 2014-05-12 FI FIEP19161861.0T patent/FI3546572T3/fi active
- 2014-05-12 SG SG10201708896WA patent/SG10201708896WA/en unknown
- 2014-05-12 EP EP19161861.0A patent/EP3546572B1/fr active Active
- 2014-05-12 EA EA201990575A patent/EA201990575A3/ru unknown
- 2014-05-12 MX MX2015015662A patent/MX2015015662A/es active IP Right Grant
- 2014-05-12 KR KR1020157035319A patent/KR102248157B1/ko active IP Right Grant
- 2014-05-12 EP EP14723436.3A patent/EP2997141B1/fr active Active
- 2014-05-12 ES ES14723436T patent/ES2930431T3/es active Active
- 2014-05-12 RS RS20221084A patent/RS63798B1/sr unknown
- 2014-05-12 SG SG11201508805UA patent/SG11201508805UA/en unknown
- 2014-05-12 LT LTEPPCT/EP2014/059662T patent/LT2997141T/lt unknown
- 2014-05-12 RU RU2015153250A patent/RU2727447C2/ru active
- 2014-05-12 EA EA201501109A patent/EA036200B1/ru unknown
- 2014-05-12 FI FIEP14723436.3T patent/FI2997141T3/fi active
- 2014-05-12 CN CN201480027071.9A patent/CN105431532B/zh active Active
- 2014-05-12 EP EP24163057.3A patent/EP4364809A2/fr active Pending
- 2014-05-12 MY MYPI2015703966A patent/MY172897A/en unknown
- 2014-05-12 SI SI201431999T patent/SI2997141T1/sl unknown
- 2014-05-12 HR HRP20221393TT patent/HRP20221393T1/hr unknown
- 2014-05-12 PL PL14723436.3T patent/PL2997141T3/pl unknown
- 2014-05-12 BR BR112015028387-0A patent/BR112015028387B1/pt active IP Right Grant
- 2014-05-12 JP JP2016513321A patent/JP6491643B2/ja active Active
- 2014-05-12 CN CN201910222072.3A patent/CN109897100A/zh active Pending
- 2014-05-12 HU HUE14723436A patent/HUE060901T2/hu unknown
- 2014-05-12 DK DK19161861.0T patent/DK3546572T3/da active
- 2014-05-12 TW TW103116744A patent/TWI636992B/zh active
- 2014-05-12 CA CA2911292A patent/CA2911292C/fr active Active
- 2014-12-05 UA UAA201512065A patent/UA118106C2/uk unknown
-
2015
- 2015-10-27 PH PH12015502479A patent/PH12015502479B1/en unknown
- 2015-11-12 SA SA515370135A patent/SA515370135B1/ar unknown
-
2016
- 2016-09-13 HK HK16110821.6A patent/HK1222678A1/zh unknown
- 2016-09-13 HK HK16110847.6A patent/HK1222679A1/zh unknown
-
2019
- 2019-03-01 JP JP2019037174A patent/JP6854307B2/ja active Active
- 2019-03-15 AU AU2019201818A patent/AU2019201818B2/en active Active
- 2019-03-26 US US16/365,588 patent/US20210000869A9/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38630A1 (fr) | Récepteur de l'antigène chimère spécifique de cd19 et ses utilisations | |
Zhang et al. | Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor | |
TR201910814T4 (tr) | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. | |
MX2017009349A (es) | Celulas inmunitarias geneticamente manipuladas para inactivacion de receptor de cleulas t, dotadas con receptores de antigenos quimericos de union a cd123 para el tratamiento de linfoma mieloide agudo o neoplasia de celulas dendriticas plasmacitoides blasticas recidivante/refractaria. | |
CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
PE20211418A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
MX2016012855A (es) | Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer. | |
AR096274A1 (es) | Receptor quimérico de antígeno específico para cd19 y sus usos | |
MX367787B (es) | Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer. | |
MX2017001229A (es) | Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer. | |
KR20190101989A (ko) | 항 gpc3 항체 | |
WO2014191113A1 (fr) | Nouveaux anticorps | |
Rataj et al. | High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy | |
RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
MX2015002760A (es) | Receptor de antigeno quimerico multi-cadena y usos del mismo. | |
MA35711B1 (fr) | Anticorps anti-alphabêtatcr | |
EA201592023A1 (ru) | Химерные молекулы fvii-xten и их применение | |
Yu et al. | Interaction between regulatory T cells and cancer stem cells | |
Wang et al. | BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma | |
CA3174090A1 (fr) | Anticorps ciblant un complexe comprenant hla-i non classique et neoantigene et leurs procedes d'utilisation | |
Kitamura et al. | Cx6Mab-1: A novel anti-mouse CXCR6 monoclonal antibody established by N-terminal peptide immunization | |
Kurosawa et al. | High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A* A24 and its application in a bispecific T-cell engager | |
PE20220217A1 (es) | Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso | |
JOP20210099A1 (ar) | مستقبلات غير طبيعية لبروتين nkg2d لا ترسل إشارات مباشرة للخلايا التي تتعلق بها | |
Babic et al. | Role of innate receptors in chronic inflammation and autoimmunity |